SCHEMBL4609462

SCHEMBL4609462

COC(=O)c1ccc(NC(=O)C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.67
CNR2 P34972 6/20 0.63
ALDH1A1 P00352 4/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
CA9 Q16790 2/20 0.58
CA12 O43570 1/20 0.58
STS P08842 1/20 0.58
P2RX2 Q9UBL9 1/20 0.55
P2RX7 Q99572 1/20 0.53
ENPP3 O14638 1/20 0.53
CA2 P00918 1/20 0.53
ENPP1 P22413 1/20 0.53
ENPP2 Q13822 1/20 0.53
HIF1A Q16665 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167370 0.84 P2RX2 (0.76) EPHX2CNR2LMNACA9CA12
SCHEMBL12443631 0.82 CNR2 (0.70) EPHX2CNR2ALDH1A1CA9CA12
SCHEMBL7707848 0.81 CNR2 (0.65) EPHX2CNR2ALDH1A1LMNACA9
SCHEMBL3324612 0.81 ALDH1A1 (0.70) CNR2ALDH1A1CA9CA12STS
SCHEMBL1549023 0.80 P2RX7 (0.73) EPHX2CNR2ALDH1A1CA9CA12
SCHEMBL19072634 0.79 P2RX2 (0.61) EPHX2CNR2CA9CA12STS
SCHEMBL5811901 0.78 CA9 (0.68) EPHX2CNR2ALDH1A1L3MBTL1CA9
SCHEMBL3321310 0.78 CA9 (0.64) EPHX2CNR2ALDH1A1CA9CA12
SCHEMBL8303597 0.78 P2RX7 (0.72) EPHX2CNR2ALDH1A1CA9CA12
SCHEMBL7705995 0.78 P2RX7 (0.71) EPHX2CNR2HTTLMNACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP disclosed
CN-100351228-C Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORP (KR) 2007-11-28 CN disclosed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US disclosed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US disclosed
CN-1839115-A Hydroxamic acid derivatives and preparation method thereof AMOREPACIFIC CORP (KR) 2006-09-27 CN disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 EPHX2 1776/4885CNR2 1396/4885ALDH1A1 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.